Retatrutide Mots C (peptidedosingprotocols.com)

How it works

The retatrutide + MOTS-c stack combines two distinct peptides that target different aspects of fat metabolism. Retatrutide (LY3437943) is a once-weekly triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors. This action leads to reduced appetite, improved insulin signaling, and increased energy expenditure. In the Phase 3 TRIUMPH-4 trial, retatrutide demonstrated a significant body weight loss of 28.7% at the highest dose of 12 mg over 68 weeks, compared to only 2.1% in the placebo group.

MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, complements retatrutide by enhancing cellular fat oxidation. It activates AMP-activated protein kinase (AMPK), which shifts muscle cells from utilizing glucose to burning fat. This mechanism is crucial because while retatrutide mobilizes fatty acids from storage, MOTS-c ensures that these fatty acids are effectively oxidized within the mitochondria, preventing them from being re-stored. This synergy is a primary reason researchers advocate for the combination of these two compounds.

The stack operates through several pathways: First, MOTS-c's activation of AMPK promotes mitochondrial fat oxidation, allowing for effective energy use from mobilized fats. Second, both peptides improve insulin sensitivity but at different levels; retatrutide enhances insulin signaling at the islet cell level, while MOTS-c improves glucose uptake in skeletal muscle. Third, MOTS-c has been linked to reduced myostatin signaling, which may help preserve lean muscle mass during caloric deficits. Lastly, MOTS-c mimics exercise effects, enhancing endurance and metabolic flexibility, which is particularly beneficial during periods of caloric restriction induced by retatrutide.

Overall, the combination of retatrutide and MOTS-c is designed to maximize fat loss while maintaining metabolic health and muscle integrity, particularly in advanced subjects or those experiencing metabolic adaptation during prolonged dieting phases. However, it is important to note that no published human trial has tested the combination of retatrutide and MOTS-c together, and the proposed mechanisms are based on individual compound research rather than direct evidence of their combined effects. [Source: Peptide Dosing Protocols]

Plain language: Retatrutide reduces appetite and increases energy use, while MOTS-c helps burn the fat that retatrutide releases from storage.

Who should avoid it

Individuals with active gastrointestinal disease should avoid this stack due to potential exacerbation of symptoms. Those with type 1 diabetes, prior pancreatitis, a history of medullary thyroid carcinoma, or active cancer are also advised against using retatrutide. Caution is recommended for anyone using metformin, berberine, or other AMPK-active medications, as these can interact with MOTS-c and increase the risk of hypoglycemia. Additionally, if gastrointestinal symptoms worsen or unusual symptoms appear, or if blood glucose levels drop unexpectedly, it is advised to pause and consult a qualified clinician. [Source: Peptide Dosing Protocols]

Plain language: People with certain medical conditions like active gastrointestinal disease or type 1 diabetes should avoid this stack.